Omid Farokhzad’s biotech insiders SPAC opens the deal window with $200M to play with
Omid Farokhzad’s SPAC is now in play after raising $200 million — triggering a green light for deal talks.
The Seer CEO, ex-Harvard professor and serial startup exec teamed with former Illumina CTO Mostafa Ronaghi on the raise, gaining the support of his MIT mentor Bob Langer on this new play.
The group behind this SPAC is deeply connected in the biotech field, upping their chances of taking a unicorn biotech into Nasdaq with a big new raise. The crew includes Mark Afrasiabi, who had co-headed the investment committee at Silver Rock Financial. There’s also CBO Rowan Chapman out of J&J Innovation and 3 independent board members: David Epstein, the former Novartis pharma chief now at Flagship, former Illumina CEO Jay Flatley and senior managing partner of the SoftBank Vision Fund, Deep Nishar.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.